Bayer’s Cardiorenal division is undergoing an impressive growth trajectory and significant R&D investment.  Bayer is committed to improving cardiorenal health both in the US and globally with currently available products and products in development, including investigational treatments for Chronic Kidney Disease (CKD), heart failure with reduced and preserved ejection fraction, and renal anemia.  Given the profound burden of CKD in Type 2 Diabetes (T2D), Bayer is making significant investmen...